End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

Lale Kostakoglu, Grzegorz S Nowakowski

Research output: Contribution to journalReview article

Abstract

“PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”

Original languageEnglish (US)
Pages (from-to)307-315
Number of pages9
JournalPET Clinics
Volume14
Issue number3
DOIs
StatePublished - Jul 1 2019

Fingerprint

Lymphoma, Large B-Cell, Diffuse
tomography
Tomography
Disease-Free Survival
progressions
Therapeutics
Meta-Analysis
Clinical Trials
drugs
Pharmaceutical Preparations

Keywords

  • Diffuse large B-cell lymphoma
  • End-of-treatment PET-CT
  • FDG-PET/CT
  • Prediction of outcome

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. / Kostakoglu, Lale; Nowakowski, Grzegorz S.

In: PET Clinics, Vol. 14, No. 3, 01.07.2019, p. 307-315.

Research output: Contribution to journalReview article

@article{02594d4004b84990802fa0a999d34c71,
title = "End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma",
abstract = "“PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”",
keywords = "Diffuse large B-cell lymphoma, End-of-treatment PET-CT, FDG-PET/CT, Prediction of outcome",
author = "Lale Kostakoglu and Nowakowski, {Grzegorz S}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.cpet.2019.03.001",
language = "English (US)",
volume = "14",
pages = "307--315",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

AU - Kostakoglu, Lale

AU - Nowakowski, Grzegorz S

PY - 2019/7/1

Y1 - 2019/7/1

N2 - “PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”

AB - “PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”

KW - Diffuse large B-cell lymphoma

KW - End-of-treatment PET-CT

KW - FDG-PET/CT

KW - Prediction of outcome

UR - http://www.scopus.com/inward/record.url?scp=85065477821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065477821&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2019.03.001

DO - 10.1016/j.cpet.2019.03.001

M3 - Review article

C2 - 31084771

AN - SCOPUS:85065477821

VL - 14

SP - 307

EP - 315

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 3

ER -